Article: Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report

Cannabis withdrawal syndrome (CWS) is characterized by irritability, sleep disorders, and physical discomfort that typically peaks within 7 days of cessation. A patient with a 30-year history of heavy cannabis developed prolonged symptoms of CWS that peaked at greater than 40 days after cessation, who was successfully managed with dexmedetomidine. This case report documents an unusual case of significantly delayed CWS peak in symptoms, as well as the novel use of dexmedetomidine for inpatient management of CWS.

Citing Articles

Psychosis associated with cannabis withdrawal: systematic review and case series.

Chesney E, Reilly T, Scott F, Slimani I, Sarma A, Kornblum D Br J Psychiatry. 2024; :1-12.

PMID: 39624030 PMC: 7617269. DOI: 10.1192/bjp.2024.175.

Considerations for Cannabinoids in Perioperative Care by Anesthesiologists.

Laudanski K, Wain J J Clin Med. 2022; 11(3).

PMID: 35160010 PMC: 8836924. DOI: 10.3390/jcm11030558.

Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?.

Claus B, Specka M, McAnally H, Scherbaum N, Schifano F, Bonnet U Front Psychiatry. 2020; 11:598150.

PMID: 33343424 PMC: 7744589. DOI: 10.3389/fpsyt.2020.598150.

References

1.

Babson K, Sottile J, Morabito D . Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017; 19(4):23. DOI: 10.1007/s11920-017-0775-9. View

2.

Cox E, Maharao N, Patilea-Vrana G, Unadkat J, Rettie A, McCune J . A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. Pharmacol Ther. 2019; 201:25-38. PMC: 6708768. DOI: 10.1016/j.pharmthera.2019.05.001. View

3.

Coursin D, Maccioli G . Dexmedetomidine. Curr Opin Crit Care. 2001; 7(4):221-6. DOI: 10.1097/00075198-200108000-00002. View

4.

Leikin J, Amusina O . Use of dexmedetomidine to treat delirium primarily caused by cannabis. Am J Emerg Med. 2017; 35(3):524.e1-524.e2. DOI: 10.1016/j.ajem.2016.10.027. View

5.

Budney A, Hughes J, Moore B, Vandrey R . Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004; 161(11):1967-77. DOI: 10.1176/appi.ajp.161.11.1967. View

6.

Bonnet U, Preuss U . The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017; 8:9-37. PMC: 5414724. DOI: 10.2147/SAR.S109576. View

7.

Cipriani F, Mancino A, Pulitano S, Piastra M, Conti G . A cannabinoid-intoxicated child treated with dexmedetomidine: a case report. J Med Case Rep. 2015; 9:152. PMC: 4490763. DOI: 10.1186/s13256-015-0636-2. View

8.

Budney A, Hughes J . The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006; 19(3):233-8. DOI: 10.1097/01.yco.0000218592.00689.e5. View

9.

Allsop D, Copeland J, Lintzeris N, Dunlop A, Montebello M, Sadler C . Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014; 71(3):281-91. DOI: 10.1001/jamapsychiatry.2013.3947. View

10.

Werneck M, Kortas G, Andrade A, Castaldelli-Maia J . A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. CNS Drugs. 2018; 32(12):1113-1129. DOI: 10.1007/s40263-018-0577-6. View

11.

Brezing C, Levin F . The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology. 2017; 43(1):173-194. PMC: 5719115. DOI: 10.1038/npp.2017.212. View

12.

Hesse M, Thylstrup B . Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers. BMC Psychiatry. 2013; 13:258. PMC: 4015312. DOI: 10.1186/1471-244X-13-258. View